Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma.
Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) may play a significant role in the treatment of patients with recurrent or in transit extremity melanoma or sarcoma that is unresectable. These procedures may be indicated when patients are otherwise faced with the possibility of a debilitating amputation. Not entirely benign treatment modalities, HILP and ILI can be associated with regional and systemic toxicities. We conducted a literature search of published studies using HILP and ILI for the treatment of extremity sarcomas and melanomas, and associated toxicities was performed. The regional toxicities of HILP and ILI are similar. The most common toxicities reported are mild to moderate. However, when severe regional toxicity occurs, albeit infrequently (<5%), fasciotomies or even amputation may be necessary. Some studies have showed a relationship between acute regional toxicities and long term regional morbidity. Systemic toxicity appears to be more frequent when TNF-alpha is used in combination with other drugs during HILP, however the use of TNF-alpha in the United States is limited to trials. Although regional toxicities are similar, systemic toxicity of ILI is minimal compared to HILP. ILI is easier to repeat, technically less complex, and may be more acceptable in infirmed patients. Long term morbidity and outcomes for ILI are still being evaluated. Both of these techniques may be suitable options in patients with unresectable advanced or recurrent, or in transit extremity melanoma or sarcoma.
Möller
Mecker G
MG
H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa. FL 33612, USA.
Lewis
James M
JM
Dessureault
Sophie
S
Zager
Jonathan S
JS
D000970:Antineoplastic Agents / Q000009:adverse effects; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects* / Q000379:methods; D002986:Clinical Trials as Topic; D003161:Compartment Syndromes / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects* / Q000379:methods; D008207:Lymphatic Metastasis / Q000517:prevention & control; D008545:Melanoma / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*; D012720:Severity of Illness Index
D000970:Antineoplastic Agents